News

Luminoah, Rivanna Medical selected to prestigious med-tech accelerator

Two Charlottesville startups have been selected to MedTech Innovator, a well-known accelerator for medical technology startups.

Luminoah and Rivanna Medical are among 65 companies selected for the Los Angeles-based accelerator’s 2025 cohort. They will participate in a four-month program geared toward accelerating a path to U.S. market success.

Luminoah and Rivanna were both selected in the diagnostic and monitoring category. Luminoah, a former Lighthouse Labs demo day winner that closed a $6 million Series A round in 2023, has developed a mobile feeding tube for patients that collects data. Rivanna offers four products using ultrasound-based imaging technology that it says offer better precision and efficiency to health care professionals.

The MedTech Innovator program will include access to MedTech Innovator’s ecosystem of manufacturers, investors, providers, patients and more. The accelerator’s alumni have collectively brought more than 400 products to market and raised roughly $10 billion in follow-on funding, according to MedTech Innovator.

The 65 selected companies will compete for a share of $800,000 in nondilutive funding. The winners will be selected by audience vote at industry conferences.

MedTech Innovator said it received nearly 1,500 applicants to the program. It ultimately invited 213 companies to pitch at road tour events in Los Angeles, Dublin and College Park, Maryland, and then whittled that field down to 65.

The cohort represents 13 countries and 17 U.S. states.

Read more here.

Recent News

07/17/2025

RIVANNA’s next-generation ultrasound guidance platform and AI-driven imaging software receive FDA 510(K) clearance

RIVANNA®, developers of world-first imaging-based medical technologies, announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) regarding the Accuro® 3S diagnostic ultrasound system and SpineNav-AI™ image processing software. This clearance authorizes the use of both technologies in United States hospital and clinical settings, providing anatomical guidance during needle or

07/15/2025

CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules

CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, announced the closing of its best-efforts offering of 1,500,000 shares of its common stock. Each share of common stock was sold at an offering price of $3.82 per share, priced at-the-market under NYSE American rules. Total gross proceeds from the

07/15/2025

Civica Appoints Dave Sehgal as Chief Manufacturing Officer and Supply Chain Officer

Civica announced the appointment of Dave Sehgal, Ph.D. as its new Chief Manufacturing Officer and Supply Chain Officer, effective July 21. In this role, Dr. Sehgal will lead Civica’s manufacturing strategy and operations, reporting directly to Ned McCoy, President and CEO. “We are excited to welcome Dave to our leadership team,” said McCoy. “His deep